In recent trading session, GSK Plc ADR (NYSE:GSK) saw 1.91 million shares changing hands at last check today with its beta currently measuring 0.49. Company’s recent per share price level of $37.65 trading at $0.08 or 0.20% at last check today assigns it a market valuation of $76.27B. That most recent trading price of GSK’s stock is at a discount of -21.62% from its 52-week high price of $45.79 and is indicating a premium of 15.75% from its 52-week low price of $31.72.
For GSK Plc ADR (GSK), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.77. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 4 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 1.15 in the current quarter.
GSK Plc ADR (NYSE:GSK) trade information
Upright in the green today for gaining 0.20%, in the last five days GSK remained trading in the green while hitting it’s week-highest on Friday, 05/16/25 when the stock touched $37.65 price level, subtracting -0.08% to its value on the day. GSK Plc ADR’s shares saw a change of 11.31% in year-to-date performance and have moved 2.80% in past 5-day. GSK Plc ADR (NYSE:GSK) showed a performance of 6.43% in past 30-days.
Wall Street analysts have assigned a consensus price target of 35.25 to the stock, which implies a fall of -6.81% to its recent value today. Analysts have been projecting 35.25 as a low price target for the stock while placing it at a high target of 35.25. It follows that stock’s current price would jump 6.37% in reaching the projected high whereas dropping to the targeted low would mean a gain of 6.37% for stock’s current value.
GSK Plc ADR (GSK) estimates and forecasts
This year revenue growth is estimated to rise 2.92% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 7.93B for the same. And 6 analysts are in estimates of company making revenue of 8.24B in the next quarter. Company posted 7.88B and 8.01B of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -11.63% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 8.89% while estimates for its earnings growth in next 5 years are of 9.03%.
GSK Plc ADR (NYSE:GSK)’s Major holders
DODGE & COX is the top institutional holder at GSK for having 68.34 million shares of worth $2.63 billion. And as of 2024-06-30, it was holding 1.6753 of the company’s outstanding shares.
The second largest institutional holder is FMR LLC, which was holding about 26.78 million shares on 2024-06-30. The number of shares represents firm’s hold over 0.6566 of outstanding shares, having a total worth of $1.03 billion.
On the other hand, Dodge & Cox Funds-Dodge & Cox Stock Fund and VANGUARD CHESTER FUNDS-Vanguard PRIMECAP Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 50.0 shares of worth $1.88 billion or 2.43% of the total outstanding shares. The later fund manager was in possession of 17.92 shares on Dec 31, 2024 , making its stake of worth around $674.18 million in the company or a holder of 0.87% of company’s stock.
